SELLAS Life Sciences Group(DE:RXK3)
€7.42+-0.40 (+3.63%)
DE:RXK3
SELLAS Life Sciences Group financials statements
€7.42
At close:+-0.40 (+3.63%)
SELLAS Life Sciences Group (RXK3) Ratios
2 Followers
SELLAS Life Sciences Group Ratios
DE:RXK3's free cash flow for Q2 2026 was $-7.59M. For the 2026 fiscal year, DE:RXK3's free cash flow was increased by $0.00 and operating cash flow was $-7.59M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 |
| Quick Ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 |
| Cash Ratio | 10.25 | 1.46 | 0.18 | 1.10 | 4.31 |
| Solvency Ratio | -3.59 | 0.06 | 0.04 | -2.54 | -3.20 |
| Operating Cash Flow Ratio | -4.05 | -3.72 | -2.29 | -1.53 | -5.22 |
| Short-Term Operating Cash Flow Coverage | -52.19 | 0.00 | 0.00 | 0.00 | -131.42 |
| Net Current Asset Value | $ 67.74M | $ 6.36M | $ -11.02M | $ 1.66M | $ 16.96M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.05 | 0.15 | 0.05 | 0.03 |
| Debt-to-Equity Ratio | 0.01 | 0.11 | -0.11 | 0.19 | 0.04 |
| Debt-to-Capital Ratio | 0.01 | 0.10 | -0.13 | 0.16 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 2.05 | -0.78 | 4.32 | 1.30 |
| Debt Service Coverage Ratio | -49.38 | 0.00 | 0.00 | 0.00 | -91.33 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.02 | 0.00 | 0.05 | 0.05 |
| Net Debt to EBITDA | 2.64 | -20.39 | -3.07 | 0.51 | 1.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 90.00% | 97.37% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -3195.00% | -257.82% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -3149.30% | -241.07% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -4195.00% | -332.82% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -4130.10% | -275.47% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -4130.10% | -272.36% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -4130.10% | -272.36% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 98.87% |
| EBT Per EBIT | 95.01% | 97.99% | 98.60% | 98.45% | 82.77% |
| Return on Assets (ROA) | -34.29% | -158.92% | -600.42% | -197.21% | -78.33% |
| Return on Equity (ROE) | -37.90% | -326.27% | 468.15% | -851.39% | -101.73% |
| Return on Capital Employed (ROCE) | -39.64% | -317.61% | 503.85% | -772.84% | -117.95% |
| Return on Invested Capital (ROIC) | -39.34% | -295.45% | 535.63% | -723.28% | -115.55% |
| Return on Tangible Assets | -35.15% | -176.28% | -867.36% | -217.04% | -84.44% |
| Earnings Yield | -6.53% | -48.52% | -14.09% | -90.23% | -24.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.03 | 0.09 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 1.14 | 10.51 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.05 | 0.29 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.10 | 0.36 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -12253.05 | -3912.80 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 12253.05 | 3912.80 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.26 | -0.58 | -0.13 | -1.23 | -1.68 |
| Free Cash Flow Per Share | -0.26 | -0.58 | -0.15 | -1.46 | -1.68 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -5.71 | -5.29 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -5.71 | -5.29 | 0.00 |
| Operating Cash Flow Coverage Ratio | -28.36 | -35.37 | -34.67 | -25.19 | -32.20 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -23.81 | -3.42 |
| Free Cash Flow Yield | -6.91% | -55.62% | -13.93% | -61.84% | -30.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -15.08 | -2.08 | -7.10 | -1.11 | -4.14 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 45.77 | 11.26 |
| Price-to-Book (P/B) Ratio | 5.80 | 6.72 | -33.22 | 9.44 | 4.21 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.48 | -1.80 | -7.18 | -1.62 | -3.29 |
| Price-to-Operating Cash Flow Ratio | -14.48 | -1.80 | -8.44 | -1.92 | -3.29 |
| Price-to-Earnings Growth (PEG) Ratio | 0.30 | 0.03 | 0.08 | -0.02 | 0.11 |
| Enterprise Value Multiple | -12.67 | 80.32 | 497.86 | -0.94 | -3.55 |
| Enterprise Value | 340.23M | 50.77M | 263.37M | 29.59M | 64.96M |
| EV to EBITDA | -12.67 | 80.32 | 497.86 | -0.94 | -3.55 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 29.59 | 8.55 |
| EV to Free Cash Flow | -11.98 | -1.43 | -7.14 | -1.05 | -2.50 |
| EV to Operating Cash Flow | -11.98 | -1.43 | -8.38 | -1.24 | -2.50 |
| Tangible Book Value Per Share | 0.63 | 0.12 | -0.04 | 0.15 | 1.19 |
| Shareholders’ Equity Per Share | 0.65 | 0.15 | -0.03 | 0.25 | 1.31 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.05 | 0.49 |
| Net Income Per Share | -0.25 | -0.50 | -0.15 | -2.13 | -1.34 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.99 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.29 | 1.07 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 30.27 | 2.81 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 12.58 | 1.49 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 1.73 | 0.13 |
| Income Quality | 1.06 | 1.15 | 0.84 | 0.58 | 1.26 |
Currency in USD
